GHK-Cu
(Copper Peptide) Calculator

• Low (1.0mg / 1000mcg): Often utilized in conservative or localized skin remodeling trials, where lower concentrations effectively stimulate basal cell regeneration, elastin production, and fibroblast activity.[1]
• Mid (2.5mg / 2500mcg): The standard median dosage in systemic literature, frequently cited in in vivo protocols observing significant upregulation of angiogenesis, collagen synthesis, and the modulation of systemic inflammatory pathways.[2]
• High (5.0mg / 5000mcg): The upper threshold typically reserved for severe acute injury models, such as accelerated burn/scald wound healing, or larger animal models requiring a robust systemic delivery of the copper-peptide complex.[3]
  

In experimental systemic protocols, GHK-Cu is most commonly administered once daily. For localized wound-healing or continuous dermatological models, researchers aim to maintain a stable, uninterrupted concentration of the copper-peptide complex to continuously signal matrix metalloproteinases and attract immune cells to the site of injury.[1]

• Subcutaneous (SubQ): The standard route for in vivo systemic research targeting generalized anti-inflammatory markers or widespread soft tissue repair. Note: Due to the chemical nature of the copper chelate, researchers often utilize higher reconstitution volumes (e.g., 2ml or 3ml of bacteriostatic water) or co-administer with compounds like BPC-157 to mitigate localized post-injection irritation (PIP) frequently observed with this specific peptide.
• Topical / Transdermal: Highly documented in dermatological research, as the low-molecular-weight GHK-Cu complex effectively penetrates the stratum corneum to stimulate local collagen, decorin, and glycosaminoglycan synthesis in the dermal matrix.[2]
  

GHK-Cu research generally follows both sub-acute and longitudinal timelines depending on the tissue remodeling goals:

• Wound Healing & Acute Repair: 2 to 4 weeks is the standard timeline for observing accelerated angiogenesis, enhanced blood vessel formation, and macroscopic wound closure in severe injury models.[3]
• Longitudinal Skin / Anti-aging Models: 8 to 12 weeks for observing sustained upregulation of structural proteins and the restoration of replicative vitality in aged or radiation-damaged fibroblasts.[1]
  

While decades of in vitro and animal models demonstrate GHK-Cu’s profound ability to accelerate tissue remodeling, attract immune cells, and modulate inflammatory pathways, it is not approved by the FDA as an injectable therapeutic for wound healing, anti-aging, or systemic inflammation in humans. All data provided is strictly for educational context, and all compounds are restricted to Research Use Only (RUO).

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
2. Dou Y, Lee A, Poon L, et al. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020;2(1):58-61. https://pmc.ncbi.nlm.nih.gov/articles/PMC8789089/
3. Wang X, Liu B, Xu Q, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. 2017;25(2):270-278. https://pubmed.ncbi.nlm.nih.gov/28370978/